Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and rival Novo Nordisk to invest billions to ramp up manufacturing.
Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and rival Novo Nordisk to invest billions to ramp up manufacturing.